p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53null or missense mutational patterns

Autor: Thompson, Emily F., Chen, Julia, Huvila, Jutta, Pors, Jennifer, Ren, Hezhen, Ho, Julie, Chow, Christine, Ta, Monica, Proctor, Lily, McAlpine, Jessica N., Huntsman, David, Gilks, C. Blake, Hoang, Lynn
Zdroj: Modern Pathology; September 2020, Vol. 33 Issue: 9 p1649-1659, 11p
Abstrakt: We have recently encountered p53 immunohistochemical (IHC) patterns in human papillomavirus (HPV)-associated carcinomas of the gynecologic tract, which were confused with absent (null) or overexpression TP53mutational staining. We therefore evaluated p53 and p16 IHC in 25 squamous cell carcinomas (SCC) (16 vulva, 4 Bartholin’s gland, and 5 cervix), 20 endocervical adenocarcinomas (EDAC), 14 high-grade squamous intraepithelial lesions (HSIL), 2 adenocarcinoma in situ (AIS), all of which exhibited morphologic features of HPV. Only cases showing diffuse/strong block-like p16 staining were included for further study. All EDACs underwent TP53sequencing and HPV in situ hybridization (ISH) was performed in selected cases. p53 IHC staining fell into two main patterns. The most common was designated as “markedly reduced (null-like)” (absence or significantly attenuated staining in >70% of cells), which could be confused with true null mutational pattern. This was present in 14/25 (56%) SCCs, 7/14 (50%) HSILs, and 18/20 (90%) EDACs. The second notable pattern was “mid-epithelial (basal sparing)” (distinct absence of staining in basal cells juxtaposed with strong staining in parabasal cells), seen in 10/25 (40%) SCC, 7/14 (50%) HSIL, and none of the EDACs. There was scattered weak to moderate p53 staining (conventional wild type) in 1/25 (4%) SCC and 2/20 (10%) EDAC. No cases showed strong/diffuse overexpression. One EDAC had a TP53missense mutation and exhibited “markedly reduced (null-like)” staining. HPV ISH revealed an inverse relationship with p53, cells positive for HPV mRNA were negative for p53. Knowledge of these patterns can help pathologists avoid misinterpreting p53 status in the setting of HPVA cancers.
Databáze: Supplemental Index